(FM) Neurología
Departamento académico
Eli Lilly and Company
Indianapolis, EE. UU.Eli Lilly and Company-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2022
-
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study
Journal of Headache and Pain, Vol. 23, Núm. 1
2021
-
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
Advances in Therapy, Vol. 38, Núm. 8, pp. 4442-4460